Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination

MLA

Dorota Zarębska-Michaluk, et al. “Loss to Follow-up of Patients after Antiviral Treatment as an Additional Barrier to HCV Elimination.” BMC Medicine, vol. 22, no. 1, Oct. 2024, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s12916-024-03699-z.

APA

Dorota Zarębska-Michaluk, Michał Brzdęk, Olga Tronina, Justyna Janocha-Litwin, Marek Sitko, Anna Piekarska, Jakub Klapaczyński, Anna Parfieniuk-Kowerda, Barbara Sobala-Szczygieł, Magdalena Tudrujek-Zdunek, Łukasz Laurans, & Robert Flisiak. (2024). Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination. BMC Medicine, 22(1), 1–11. https://doi.org/10.1186/s12916-024-03699-z

Chicago

Dorota Zarębska-Michaluk, Michał Brzdęk, Olga Tronina, Justyna Janocha-Litwin, Marek Sitko, Anna Piekarska, Jakub Klapaczyński, et al. 2024. “Loss to Follow-up of Patients after Antiviral Treatment as an Additional Barrier to HCV Elimination.” BMC Medicine 22 (1): 1–11. doi:10.1186/s12916-024-03699-z.